Our key Figures

21,700 employees

in 149 countries, including 4,500 in France.

5 major R&D areas

cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.

94 Million patients

treated daily with Servier medicinal products and generics.

49 servier drugs

on the global market

36 drug candidates

in research and development, including 26 new molecular entities.

16 international centers of clinical development

and 3 research centers.

16 chemical and pharmaceutical production sites

producing chemicals and pharmaceuticals worldwide.

4,152 billion euros turnover

comprising 2.94 billion euros for Servier and 1.21 billion euros for generics.

25 % of turnover from Servier drugs is invested in R&D

excluding generics.

No. 2 pharmaceutical company in france

no. 30 in the world; 3 research centres including 2 in France.

No.1 in cardiology in France

no. 2 in Europe, No. 8 in the world.

 

2nd leading preferred partner for research centers conducting clinical trials

According to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies

 

Servier earned the highest score of A3++

As in previous years, this high score represents excellence in honoring financial commitments.

 

Participation reached 47.3% of the trade balance surplus in france

In pharmaceuticals and fine chemicals, amouting to 1.51 billion euros.